Quimox

Adult ≥18 yr w/ acute exacerbation of chronic bronchitis, community-acquired pneumonia, acute sinusitis, skin & skin structure, abdominal infection due to polymicrobial in patients w/ alternative agent intolerance.

400 mg once daily. Duration of therapy: Acute exacerbation of chronic bronchitis 5-10 days. Community-acquired pneumonia 10 days. Acute sinusitis 7 days. Skin & skin structure 7-21 days (IV/oral consecutively). Intra-abdominal infections 5-14 days (IV/oral consecutively).

Hypersensitivity to moxifloxacin or other quinolones. History of tendon disease or quinolone treatment-related diseases. Prolonged or documented QT interval, electrolyte imbalance especially hypokalemia; bradycardia, clinically relevant heart failure w/ reduced left ventricular ejection fraction; history of symptomatic arrhythmia. Impaired hepatic function, increased transaminase level >5-fold ULN, CrCl <30 mL/min, undergoing renal dialysis. Pregnancy & lactation. Patient <18 yr.

Discontinue use if cardiac arrhythmia occurs. Not to be used for treatment of MRSA infections. Perform LFT if liver dysfunction occurs. Tendinitis & tendon rupture. Patients w/ CNS disorders; severe diarrhea during or after treatment; myasthenia gravis, pelvic inflammatory disease; psychosis or history of mental disorders. Family history of G6PD deficiency. Patients receiving other drugs which may reduce K & Mg level. DM patients who are receiving oral hypoglycaemics or insulin. Avoid extensive UV or sunlight exposure during treatment. May affect ability to drive & use machines. Severe liver dysfunction. Female. Elderly.

Systemic superinfection; anemia, leucopenia, neutropenia, thrombocytopenia, thrombocytemia, prolonged prothrombin time/INR, thromboplastine abnormalities; allergic reactions, pruritus, rash, urticaria; hyperlipidemia; nervousness, psychomotor hyperactivity/agitation; paresthesia &/or dysesthesia, taste & sleep disturbances, mental confusion & disorientation, tremor, vertigo, drowsiness; visual disturbances; QT prolongation, palpitation, tachycardia, vasodilatation; dyspnea; reduced appetite, constipation, dyspepsia, bloating, gastroenteritis, increased amylase; liver disorders, increased bilirubin, γ-glutamyl-transferase & alkaline phosphatase level; arthralgia, myalgia; dehydration; malaise, unspecified pain, sweating.

Mg- or Al-containing antacids, didanosine, sucralfate, Fe- or Zn-containing agents; neuroleptic agents, antimalarial agents, antimycotic azole, macrolide, certain antihistamine eg, terfenadine, astemizole, cisapride.

Quinolones

J01MA14 - moxifloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.

K